We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Infinity Pharmaceuticals Focuses on Lead Candidate IPI-549
Read MoreHide Full Article
We issued an updated report on Infinity Pharmaceuticals, Inc. on Apr 7.
Infinity’s share price shows that the company has outperformed the Zacks classified Medical Drugs industry year to date. The stock rose 79.3% compared with the industry’s gain of 0.2%.
The company is currently focused on the development of its lead immuno-oncology candidate, IPI-549. In Nov 2016, it had entered into a clinical trial collaboration with Bristol-Myers Squibb Company (BMY - Free Report) to evaluate IPI-549 in combination with the latter’s checkpoint inhibitor Opdivo in patients with advanced solid tumors. Once the dose-escalation phase on the combination is complete, an expansion phase will evaluate the combination in patients with selected solid tumors, including non-small cell lung cancer (NSCLC), melanoma and squamous cell carcinoma of the head and neck (SCCHN) in the second half of 2017. In 2017, Infinity plans to report phase I data from the monotherapy dose-escalation phase and the IPI-549 plus Opdivo dose-escalation phase.
In fact, Infinity’s progress with IPI-549 has been impressive. Moreover, clinical trial collaboration with Bristol-Myers has provided the company with a strong partner with expertise in the field of immuno-oncology. In addition, it is likely to allow Infinity to expedite the development of IPI-549.
In Oct 2016, the company entered into a license agreement with Verastem under which it granted exclusive worldwide rights to develop and commercialize its oncology candidate duvelisib to the latter. The agreement will see Infinity receiving up to $28 million across two milestone payments – $6 million upon positive data (currently anticipated in the first half of 2017) from the randomized monotherapy phase III DUO study in patients with relapsed/refractory CLL and $22 million upon the first regulatory approval of duvelisib inside or outside of the U.S. In addition, Infinity is eligible to receive tiered mid-to-high single-digit royalties on net sales of duvelisib, subject to approval. It will also be responsible for the royalties on net sales of duvelisib owed by the company to Mundipharma International Corporation and Purdue Pharmaceutical. Overall, we are optimistic about the deal as it is expected to provide Infinity with much needed funds.
In fact, Infinity has undergone a total of four restructuring drives since Jun 2016. This, in turn, has led to reduction of its employee headcount by an aggregate of 174 positions, representing approximately 79% from the Dec 31, 2015. The company also announced that it will grant the rights to develop and commercialize duvelisib to Verastem. The company is also evaluating its current facility leases.
But besides IPI-549, Infinity has no approved product in its portfolio at the moment. This has led the company to totally depend on this particular candidate for growth. Consequently, too much focus on the successful development and approval of only one candidate might result in regulatory setbacks related to IPI-549.
Currently, Infinity faces stiff competition in the fields of immuno-oncology from companies like Bristol-Myers, AstraZeneca Plc (AZN - Free Report) , Celgene, Merck, Novartis, Pfizer, Roche and Eli Lilly and Company (LLY - Free Report) among others.
While we share many recommendations and ideas with the public, certain moves are hidden from everyone but selected members of our portfolio services. Would you like to peek behind the curtain today and view them?
Starting now, for the next month, I invite you to follow all Zacks' private buys and sells in real time from value to momentum...from stocks under $10 to ETF to option movers...from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors.
Image: Bigstock
Infinity Pharmaceuticals Focuses on Lead Candidate IPI-549
We issued an updated report on Infinity Pharmaceuticals, Inc. on Apr 7.
Infinity’s share price shows that the company has outperformed the Zacks classified Medical Drugs industry year to date. The stock rose 79.3% compared with the industry’s gain of 0.2%.
The company is currently focused on the development of its lead immuno-oncology candidate, IPI-549. In Nov 2016, it had entered into a clinical trial collaboration with Bristol-Myers Squibb Company (BMY - Free Report) to evaluate IPI-549 in combination with the latter’s checkpoint inhibitor Opdivo in patients with advanced solid tumors. Once the dose-escalation phase on the combination is complete, an expansion phase will evaluate the combination in patients with selected solid tumors, including non-small cell lung cancer (NSCLC), melanoma and squamous cell carcinoma of the head and neck (SCCHN) in the second half of 2017. In 2017, Infinity plans to report phase I data from the monotherapy dose-escalation phase and the IPI-549 plus Opdivo dose-escalation phase.
In fact, Infinity’s progress with IPI-549 has been impressive. Moreover, clinical trial collaboration with Bristol-Myers has provided the company with a strong partner with expertise in the field of immuno-oncology. In addition, it is likely to allow Infinity to expedite the development of IPI-549.
In Oct 2016, the company entered into a license agreement with Verastem under which it granted exclusive worldwide rights to develop and commercialize its oncology candidate duvelisib to the latter. The agreement will see Infinity receiving up to $28 million across two milestone payments – $6 million upon positive data (currently anticipated in the first half of 2017) from the randomized monotherapy phase III DUO study in patients with relapsed/refractory CLL and $22 million upon the first regulatory approval of duvelisib inside or outside of the U.S. In addition, Infinity is eligible to receive tiered mid-to-high single-digit royalties on net sales of duvelisib, subject to approval. It will also be responsible for the royalties on net sales of duvelisib owed by the company to Mundipharma International Corporation and Purdue Pharmaceutical. Overall, we are optimistic about the deal as it is expected to provide Infinity with much needed funds.
In fact, Infinity has undergone a total of four restructuring drives since Jun 2016. This, in turn, has led to reduction of its employee headcount by an aggregate of 174 positions, representing approximately 79% from the Dec 31, 2015. The company also announced that it will grant the rights to develop and commercialize duvelisib to Verastem. The company is also evaluating its current facility leases.
But besides IPI-549, Infinity has no approved product in its portfolio at the moment. This has led the company to totally depend on this particular candidate for growth. Consequently, too much focus on the successful development and approval of only one candidate might result in regulatory setbacks related to IPI-549.
Currently, Infinity faces stiff competition in the fields of immuno-oncology from companies like Bristol-Myers, AstraZeneca Plc (AZN - Free Report) , Celgene, Merck, Novartis, Pfizer, Roche and Eli Lilly and Company (LLY - Free Report) among others.
Infinity Pharmaceuticals, Inc. Price
Infinity Pharmaceuticals, Inc. Price | Infinity Pharmaceuticals, Inc. Quote
Zacks Rank
Infinity currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Zacks' Hidden Trades
While we share many recommendations and ideas with the public, certain moves are hidden from everyone but selected members of our portfolio services. Would you like to peek behind the curtain today and view them?
Starting now, for the next month, I invite you to follow all Zacks' private buys and sells in real time from value to momentum...from stocks under $10 to ETF to option movers...from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors.
Click here for Zacks' secret trade>>